Notably, a subgroup of patients with T2DM (16%) was able to discontinue their rapid-acting insulin before meals and effectively manage their condition solely with oral anti-diabetic medications and/or weekly injectable GLP-1 receptor agonists after transitioning from SMBG to CGM. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.